iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics

iBio, Inc., a leading AI-driven innovator of precision antibody immunotherapies, is set to make waves at the upcoming Festival of Biologics in Basel, Switzerland. The company’s Vice President of Platform Technologies and Machine Learning, Matt Greving, Ph.D., has been selected to present on iBio’s groundbreaking technology for enhancing bispecific T-cell engagers (TCE).

The Festival of Biologics is a prestigious conference that brings together industry leaders from pharma, biotech, and academic and research institutions to discuss the latest advancements in biologics and antibody-based therapeutics. Dr. Greving’s presentation, titled “Enhancing Bispecific T Cell Engager Discovery, Potency, Safety and Developability with Machine Learning and Mammalian Display,” will provide valuable insights into iBio’s technology stack.

iBio’s technology stack includes epitope engineering, a fully human antibody library, and EngageTx™ for bispecific optimization. These cutting-edge tools have the potential to overcome challenges in the discovery of bispecific TCEs, which hold great promise in the field of cancer immunotherapies. Bispecific antibodies have the unique ability to guide human immune cells to attack and destroy tumor cells with a single molecule, making them a crucial area of research in the fight against cancer.

During his presentation, Dr. Greving will showcase data demonstrating how iBio’s machine learning-driven epitope steering and mammalian-display antibody libraries efficiently discover diverse TCE arms that are finely tuned for potency, toxicity, developability, and cyno cross-reactivity. This breakthrough technology has the potential to revolutionize the development of next-generation CD3-T cell engager bispecifics.

Dr. Greving’s expertise in the field of AI and machine learning extends beyond his presentation. He will also chair a session titled “Pitfalls to Avoid When Building an AI-Driven Platform Company,” further highlighting iBio’s commitment to leveraging cutting-edge technologies to drive innovation in the biopharmaceutical industry.

iBio’s mission is to develop next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes. By prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases, iBio aims to decrease drug failures, shorten drug development timelines, and open up new frontiers in the fight against the most promising targets.

The company’s patented AI-powered tech stack, including EngageTx, offers an accelerated solution to generating bispecific antibodies. With its ability to optimize next-gen CD3-T cell engager bispecifics, iBio is well-positioned to tackle hard-to-drug targets both internally and through collaborations with partners.

While iBio acknowledges the inherent risks and uncertainties in the biopharmaceutical industry, the company remains confident in its ability to execute its growth strategy. iBio’s commitment to obtaining regulatory approvals, promoting and commercializing its product candidates, and fostering a competitive edge sets it apart as a leader in the field.

As iBio continues to push the boundaries of precision antibody immunotherapies, the company’s presence at the Festival of Biologics serves as a testament to its dedication to advancing the field and improving patient outcomes. With its innovative technology and visionary leadership, iBio is poised to make a significant impact in the fight against cancer and other challenging diseases.

For more information on iBio and its groundbreaking work, visit www.ibioinc.com.

Leave a comment